WILMETTE, Ill. - Monopar Therapeutics Inc . (NASDAQ:MNPR), a biopharmaceutical company engaged in the development of cancer treatments, today announced new preclinical imaging data showing favorable uptake of its radioisotope therapy in tumors.
This follows earlier data released on February 22, which combined diagnostic and therapeutic imaging results using the company's proprietary MNPR-101 agent.
The recent findings demonstrate a high specificity and durable uptake of MNPR-101 conjugated with Lutetium-177 (Lu-177) in a pancreatic cancer model, suggesting potential for targeted treatment of uPAR-positive cancers.
Monopar's Chief Operating Officer, Andrew Cittadine, highlighted the importance of the data in explaining the significant tumor elimination observed in preclinical studies.
Monopar's progress includes the clearance to begin a Phase 1 dosimetry clinical trial in Australia, which will evaluate MNPR-101-Zr in advanced cancer patients. The company aims to develop a radiodiagnostic and radiotherapeutic pairing for imaging and treating aggressive cancers such as triple negative breast cancer and pancreatic cancer.
The company's pipeline also includes camsirubicin for advanced soft tissue sarcoma and an early-stage camsirubicin analog, MNPR-202. Despite the positive preclinical results, Monopar acknowledges the risks and uncertainties inherent in the development and commercialization of new treatments.
The latest data support Monopar's ongoing efforts and may enhance investor confidence in the potential clinical benefit of MNPR-101-based radiopharmaceuticals. The information in this article is based on a press release statement from Monopar Therapeutics Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.